Terumo BCT and Steminent push automation into the fragile world of stem cell manufacturing
MSC science is advancing faster than manufacturing can scale. Terumo BCT and Steminent are testing whether automation can close that gap.
Pharma & Biotech
Pharma & Biotech
What OrganaBio’s Excellos asset acquisition reveals about next-generation CDMO demand
Cell therapy needs redundancy, not just cleanrooms. OrganaBio’s Excellos deal tests whether bicoastal CDMO scale can reduce developer risk.
Pharma & Biotech
Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.